<DOC>
	<DOCNO>NCT00049400</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop tumor cell divide stop grow die . PURPOSE : This phase I trial study side effect best dose ixabepilone treating patient advance solid tumor lymphomas liver dysfunction .</brief_summary>
	<brief_title>S0355 Ixabepilone Treating Patients With Advanced Solid Tumors Lymphomas Liver Dysfunction</brief_title>
	<detailed_description>OBJECTIVES : - Determine level hepatic impairment dose modification ixabepilone require patient advance solid tumor lymphomas vary level liver dysfunction . - Determine effect hepatic dysfunction plasma pharmacokinetics drug patient . - Determine toxic effect drug varying level hepatic dysfunction patient . OUTLINE : This dose-escalation , multicenter study . Patients stratify accord liver function ( normal v mild dysfunction v moderate dysfunction v severe dysfunction ) . Patients receive ixabepilone IV 3 hour day 1 . Courses repeat every 3 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos ixabepilone maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , least 6 12 patient treat recommended phase II dose . Patients follow 30 day . PROJECTED ACCRUAL : A total 12-84 patient ( 6-12 stratum 1 ; 2-18 stratum 2 ; 2-24 stratum 3 ; 2-30 stratum 4 ) accrue study within 12 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm solid tumor lymphoma standard curative palliative measure exist longer effective Pathological confirmation diagnosis require patient liver mass , raise alphafetoprotein level ( least 500 ng/mL ) , positive serology hepatitis consistent diagnosis hepatocellular carcinoma Any solid tumor lymphoma tumor type eligible Must thoracic upper abdominal CT scan , include entire liver adrenal , within 28 day study entry Patients glioma brain metastasis must stable dose corticosteroid seizurefree past month Prior whole brain gamma knife radiotherapy require know brain metastases No unstable untreated ( nonirradiated ) brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 No active hemolysis Hepatic See Disease Characteristics Patients biliary obstruction shunt place allow shunt place least 10 day liver function stable Abnormal liver function ( bilirubin SGOT ) allow regardless cause ( metastasis cause ) No evidence biliary sepsis Renal Creatinine great 1.5 mg/dL Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other No concurrent uncontrolled illness No ongoing active infection No uncontrolled diarrhea No peripheral neuropathy grade II great No psychiatric illness social situation would preclude study compliance HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy malignancy Chemotherapy More 2 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) No concurrent chemotherapy malignancy Endocrine therapy See Disease Characteristics No concurrent oral contraceptives No concurrent hormone therapy malignancy Concurrent luteinizing hormonereleasing hormone agonist allow Radiotherapy See Disease Characteristics More 4 week since prior radiotherapy recover No concurrent radiotherapy malignancy Surgery More 2 week since prior major surgery Other Recovered prior therapy No concurrent medication know inhibitor CYP3A4</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>primary central nervous system lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 , 2 , 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma Hodgkin lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV grade 1 , 2 , 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma MALT</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
</DOC>